Healthcare provider profile · identity verified

Robert Andre De Roziere, FNP

Nurse Practitioner · DAYTON, OH · NPI 1396200523

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	285	65
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	248	72
Lorazepam	Lorazepam	212	56
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	196	37
Oxycodone Hcl	Oxycodone Hcl	169	47
Sertraline Hcl	Sertraline Hcl	162	36
Furosemide	Furosemide	151	48
Divalproex Sodium	Divalproex Sodium	127	27
Tramadol Hcl	Tramadol Hcl	127	42
Levothyroxine Sodium	Levothyroxine Sodium	125	36
Gabapentin	Gabapentin	119	38
Amlodipine Besylate	Amlodipine Besylate	112	34
Potassium Chloride	Potassium Chloride	107	31
Trazodone Hcl	Trazodone Hcl	107	37
Pantoprazole Sodium	Pantoprazole Sodium	100	32
Metformin Hcl	Metformin Hcl	99	26
Buspirone Hcl	Buspirone Hcl	86	23
Eliquis	Apixaban	84	25
Losartan Potassium	Losartan Potassium	82	22
Mirtazapine	Mirtazapine	82	31
Tamsulosin Hcl	Tamsulosin Hcl	77	22
Lisinopril	Lisinopril	72	23
Donepezil Hcl	Donepezil Hcl	69	23
Metoprolol Tartrate	Metoprolol Tartrate	67	28
Quetiapine Fumarate	Quetiapine Fumarate	66	18
Omeprazole	Omeprazole	61	21
Hydroxyzine Pamoate	Hydroxyzine Pamoate	57	31
Olanzapine	Olanzapine	56	suppressed
Allopurinol	Allopurinol	55	suppressed
Pregabalin	Pregabalin	52	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	48	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	48	14
Glipizide Er	Glipizide	47	suppressed
Lacosamide	Lacosamide	47	suppressed
Prednisone	Prednisone	47	27
Levetiracetam	Levetiracetam	45	suppressed
Clonazepam	Clonazepam	42	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	42	11
Galantamine Hbr	Galantamine Hbr	40	suppressed
Benztropine Mesylate	Benztropine Mesylate	39	suppressed
Glipizide	Glipizide	39	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	38	28
Ondansetron Hcl	Ondansetron Hcl	38	29
Clopidogrel	Clopidogrel Bisulfate	36	15
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	36	28
Metoprolol Succinate	Metoprolol Succinate	34	12
Methocarbamol	Methocarbamol	33	21
Montelukast Sodium	Montelukast Sodium	33	suppressed
Baclofen	Baclofen	32	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	13
Januvia	Sitagliptin Phosphate	32	suppressed
Celecoxib	Celecoxib	31	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	31	suppressed
Nystatin	Nystatin	31	17
Risperidone	Risperidone	31	suppressed
Carvedilol	Carvedilol	30	14
Ceftriaxone	Ceftriaxone Sodium	30	21
Escitalopram Oxalate	Escitalopram Oxalate	30	12
Memantine Hcl	Memantine Hcl	30	14
Bupropion Xl	Bupropion Hcl	29	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Alprazolam	Alprazolam	26	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	26	20
Famotidine	Famotidine	26	13
Azithromycin	Azithromycin	25	20
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Finasteride	Finasteride	25	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	25	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Fenofibrate	Fenofibrate,micronized	24	suppressed
Levofloxacin	Levofloxacin	24	17
Midodrine Hcl	Midodrine Hcl	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	17
Fluticasone Propionate	Fluticasone Propionate	22	18
Simvastatin	Simvastatin	22	suppressed
Aripiprazole	Aripiprazole	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Myrbetriq	Mirabegron	21	suppressed
Topiramate	Topiramate	21	suppressed
Tresiba Flextouch U-100	Insulin Degludec	21	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	21	suppressed
Fluconazole	Fluconazole	20	13
Hydralazine Hcl	Hydralazine Hcl	20	12
Lidocaine Hcl	Lidocaine Hcl	20	17
Hydrochlorothiazide	Hydrochlorothiazide	19	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	18	16
Ezetimibe	Ezetimibe	18	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	18	14
Lactulose	Lactulose	18	suppressed
Meloxicam	Meloxicam	18	suppressed
Ramelteon	Ramelteon	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Ibuprofen	Ibuprofen	17	14
Lansoprazole	Lansoprazole	17	suppressed
Briviact	Brivaracetam	16	suppressed
Cephalexin	Cephalexin	16	15
Diltiazem 24hr Er	Diltiazem Hcl	16	suppressed
Latanoprost	Latanoprost	16	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Zonisamide	Zonisamide	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	13
Calcium Acetate	Calcium Acetate	15	suppressed
Humalog	Insulin Lispro	15	suppressed
Klayesta	Nystatin	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Nyamyc	Nystatin	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Premarin	Estrogens, Conjugated	15	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	14	suppressed
Clindamycin Hcl	Clindamycin Hcl	14	11
Haloperidol	Haloperidol	14	suppressed
Jardiance	Empagliflozin	14	suppressed
Perphenazine	Perphenazine	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Eletriptan Hbr	Eletriptan Hydrobromide	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Alendronate Sodium	Alendronate Sodium	12	suppressed
Clonidine	Clonidine	12	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Temazepam	Temazepam	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error